Stock market today: S&P 500 ends lower, but tech bounce on dip-buying stems losses
Iqvia Holdings Inc’s stock reached a 52-week high, touching 225.07 USD, reflecting a significant milestone for the company in the stock market. As of the latest trading session, the stock sits at 225.31 USD, slightly above this threshold. According to InvestingPro data, the RSI suggests the stock is currently in overbought territory. Over the past year, Iqvia has experienced a 10.84% increase in its stock value, underscoring a period of growth and investor confidence. More impressively, the stock has surged 46.59% over the past six months and 12.4% year-to-date. This achievement places Iqvia’s stock at the pinnacle of its performance for the year, highlighting the company’s positive trajectory and market position. Analysts appear optimistic, with a consensus recommendation leaning toward "Buy" and price targets ranging from 200 USD to 268 USD. As Iqvia continues to expand its influence in the healthcare sector, this 52-week high serves as a testament to its robust business strategy and market appeal. InvestingPro identifies Iqvia as a prominent player in the Life Sciences Tools & Services industry, with management aggressively buying back shares. The stock is trading slightly below its Fair Value estimate, despite its P/E ratio of 30.17. Discover 10 more exclusive ProTips and comprehensive analysis in the Pro Research Report, available for Iqvia and 1,400+ top US stocks through InvestingPro.
In other recent news, IQVIA Holdings Inc. reported its third-quarter earnings for 2025, surpassing analyst expectations with an adjusted diluted earnings per share of $3.00, slightly above the forecast of $2.97. Revenue for the quarter reached $4.1 billion, also exceeding expectations of $4.08 billion. Despite these positive earnings results, the company experienced a downgrade from TD Cowen, which changed its stock rating from Buy to Hold, citing valuation concerns. However, Baird upgraded IQVIA’s stock rating from Neutral to Outperform, pointing to a recovery in research and development as a key factor for the upgrade.
In governance news, Nobel laureate Dr. William G. Kaelin Jr. has joined IQVIA’s board of directors. This appointment brings his expertise in physiology and medicine to the company’s leadership. Meanwhile, NEXT Oncology, an Avacare business, has expanded its Phase I cancer clinical trial services to Japan through a partnership with Kansai Medical University. This collaboration marks Osaka as the newest location in NEXT Oncology’s global network.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.